Cargando…
Immunotherapy for the treatment of multiple myeloma
Despite advances in treatment for multiple myeloma, the majority of patients ultimately develop relapsed disease marked by immune evasion and resistance to standard therapy. Immunotherapy has emerged as a powerful tool for tumor-directed cytotoxicity with the unique potential to induce immune memory...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649817/ https://www.ncbi.nlm.nih.gov/pubmed/36389674 http://dx.doi.org/10.3389/fimmu.2022.1027385 |
_version_ | 1784827879467515904 |
---|---|
author | Boussi, Leora S. Avigan, Zachary M. Rosenblatt, Jacalyn |
author_facet | Boussi, Leora S. Avigan, Zachary M. Rosenblatt, Jacalyn |
author_sort | Boussi, Leora S. |
collection | PubMed |
description | Despite advances in treatment for multiple myeloma, the majority of patients ultimately develop relapsed disease marked by immune evasion and resistance to standard therapy. Immunotherapy has emerged as a powerful tool for tumor-directed cytotoxicity with the unique potential to induce immune memory to reduce the risk of relapse. Understanding the specific mechanisms of immune dysregulation and dysfunction in advanced myeloma is critical to the development of further therapies that produce a durable response. Adoptive cellular therapy, most strikingly CAR T cell therapy, has demonstrated dramatic responses in the setting of refractory disease. Understanding the factors that contribute to immune evasion and the mechanisms of response and resistance to therapy will be critical to developing the next generation of adoptive cellular therapies, informing novel combination therapy, and determining the optimal time to incorporate immune therapy in the treatment of myeloma. |
format | Online Article Text |
id | pubmed-9649817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96498172022-11-15 Immunotherapy for the treatment of multiple myeloma Boussi, Leora S. Avigan, Zachary M. Rosenblatt, Jacalyn Front Immunol Immunology Despite advances in treatment for multiple myeloma, the majority of patients ultimately develop relapsed disease marked by immune evasion and resistance to standard therapy. Immunotherapy has emerged as a powerful tool for tumor-directed cytotoxicity with the unique potential to induce immune memory to reduce the risk of relapse. Understanding the specific mechanisms of immune dysregulation and dysfunction in advanced myeloma is critical to the development of further therapies that produce a durable response. Adoptive cellular therapy, most strikingly CAR T cell therapy, has demonstrated dramatic responses in the setting of refractory disease. Understanding the factors that contribute to immune evasion and the mechanisms of response and resistance to therapy will be critical to developing the next generation of adoptive cellular therapies, informing novel combination therapy, and determining the optimal time to incorporate immune therapy in the treatment of myeloma. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9649817/ /pubmed/36389674 http://dx.doi.org/10.3389/fimmu.2022.1027385 Text en Copyright © 2022 Boussi, Avigan and Rosenblatt https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Boussi, Leora S. Avigan, Zachary M. Rosenblatt, Jacalyn Immunotherapy for the treatment of multiple myeloma |
title | Immunotherapy for the treatment of multiple myeloma |
title_full | Immunotherapy for the treatment of multiple myeloma |
title_fullStr | Immunotherapy for the treatment of multiple myeloma |
title_full_unstemmed | Immunotherapy for the treatment of multiple myeloma |
title_short | Immunotherapy for the treatment of multiple myeloma |
title_sort | immunotherapy for the treatment of multiple myeloma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649817/ https://www.ncbi.nlm.nih.gov/pubmed/36389674 http://dx.doi.org/10.3389/fimmu.2022.1027385 |
work_keys_str_mv | AT boussileoras immunotherapyforthetreatmentofmultiplemyeloma AT aviganzacharym immunotherapyforthetreatmentofmultiplemyeloma AT rosenblattjacalyn immunotherapyforthetreatmentofmultiplemyeloma |